Idiopathic breakthrough pain: A New Hypothesis

Clinical Drug Investigation

Volumn 30, Issue SUPPL. 2, 2010, Pages 27-29

  Sabato, Alessandro Fabrizio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PAIN; CHRONIC PAIN; MICROGLIA; PRIORITY JOURNAL; REVIEW; SYNAPSE; CHRONIC DISEASE; DRUG EFFECTS; HUMAN; METABOLISM; PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANALGESIC AGENT;

ANALGESICS; CHRONIC DISEASE; HUMANS; MICROGLIA; PAIN; PAIN THRESHOLD; SIGNAL TRANSDUCTION;

EID: 77955116132     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1158410-S0-000000000-00000     Document Type: Review

References (22)

1. Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain 2000 Sep; 16 (3 Suppl.): S144-56
2. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005 Apr; 9 (2): 195-206
3. Mercadante S, Villari P, Ferrera P, et al. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 2010 May; 26 (4): 306-309
4. Davis MP. Recent development in therapeutics for breakthrough pain. Expert RevNeurother 2010May; 10 (5): 757-773
5. Portenoy RK, Forbes K, Lussier D, et al. Difficult pain problems: an integrated approach. In: Doyle D, Hanks G, Cherny N, et al. editors. Oxford Textbook of Palliative Medicine, 3rd ed.Oxford: Oxford University Press; 2004. 438-458
6. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990 Jun; 41 (3): 273-281
7. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999 May; 81 (1-2): 129-134
8. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13 (4): 331-338
9. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002 Feb 1; 94 (3): 832-839
10. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. Aninternational survey. PalliatMed 2004Apr; 18 (3): 177-183
11. Inoue K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 2006 Jan; 109 (1-2): 210-226
12. Inoue K, Tsuda M. Microglia and neuropathic pain. Glia 2009 Nov 1; 57 (14): 1469-1479
13. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010 Apr; 1802 (4): 396-405
14. Zhuang ZY, Xu H, Clapham DE, et al. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 2004 Sep 22; 24 (38): 8300-8309
15. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009 Jan; 10 (1): 23-36
16. Ledeboer A, Sloane EM, Milligan ED, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005 May; 115 (1-2): 71-83
17. Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996 Nov; 19 (11): 514-520
18. Facci L, Dal Toso R, Romanello S, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995 Apr 11; 92 (8): 3376-3380
19. Costa B, Comelli F, Bettoni I, et al. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008 Oct 31; 139 (3): 541-550
20. Pivneva TA. Microglia in normal condition and pathology. Fiziol Zh 2008; 54 (5): 81-89
21. Hains LE, Loram LC, Weiseler JL, et al. Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain. Epub 2010 Apr 29
22. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008 May-Jun; 60 (3): 297-307.